Response to: Correspondence on “Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure” by Yalta et al
- 16 October 2021
- Vol. 107 (23), 1922.2-1923
- https://doi.org/10.1136/heartjnl-2021-320174
Abstract
No abstract availableKeywords
Funding Information
- Medical Research Council (TS, MR/T029153/1)
- Wellcome Trust (DEN, WT103782AIA)
- British Heart Foundation (SJ FS/CRTF/20/24087 and RE/18/5/3, DEN CH/09/002,)
This publication has 9 references indexed in Scilit:
- Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failureHeart, 2021
- Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trialThe Lancet, 2020
- Trimetazidine-Induced Parkinsonism: A Systematic ReviewFrontiers in Neurology, 2020
- Effect of Trimetazidine on Diabetic Patients with Coronary Heart Diseases: A Meta-Analysis of Randomized, Controlled TrialsChinese Medical Sciences Journal, 2020
- Inhibition of Sodium Glucose Cotransporters Improves Cardiac PerformanceInternational Journal of Molecular Sciences, 2019
- Metabolic Recovery of the Failing Heart: Emerging Therapeutic OptionsMethodist DeBakey Cardiovascular J, 2017
- Trimetazidine: a meta-analysis of randomised controlled trials in heart failureHeart, 2010
- The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A ThiolaseCirculation Research, 2000